Abstract 13729: Monotherapy With a P2Y12 Inhibitor versus Aspirin for Secondary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) Events: A Meta-Analysis of Randomized Trials

• Published in: Circulation (New York, N.Y.) N.Y.), 2021-11, Vol.144 (Suppl_1), p.A13729-A13729
• Main Authors: Chunawala, Zainali, Aggarwal, Devika, Bhatia, Kirtipal S, jain, vardhmaan, Mukherjee, Debabrata, Baber, Usman, Bangalore, Sripal, NAVARESE, ELIANO, Levisay, Justin p, Mishkel, Gregory, Ricciardi, Mark, Vaduganathan, Muthiah, Furtado, Remo, Zelniker, Thomas A, Qamar, Arman
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.144.suppl_1.13729

BackgroundAspirin is the most frequently used antiplatelet monotherapy for secondary prevention in patients with established ASCVD. Trials comparing monotherapy with a P2Y12i versus aspirin have shown variable results. MethodsMedline, Embase, & Cochrane Central databases were searched to identify RCTs comparing monotherapy with a P2Y12i versus aspirin for secondary prevention in patients with established ASCVD (ischemic stroke, coronary, or peripheral artery disease). The primary outcome of interest was major adverse cardiac events (MACE). Secondary outcomes were myocardial infarction (MI), stroke, all-cause mortality, & major bleeding. The DerSimonian and Laird random-effects model was used to calculate risk ratios (RR) & the corresponding 95% confidence interval (CI). Heterogeneity among studies was assessed using the Higgins I2 value. Results9 eligible RCTs (5 with clopidogrel & 4 with ticagrelor) with 62,336 patients were included in our analyses. Monotherapy with P2Y12i significantly reduced the risk of MACE by 11% (0.89, 95% CI 0.84 - 0.95, I2 =0), & MI by 19% (0.81, 95% CI 0.71 - 0.92, I2=0) as compared with aspirin monotherapy (Figure). There was no significant difference in the risk of stroke (0.85, 95% CI 0.73-1.01), & all-cause mortality (1.01, 95% CI 0.92 - 1.11) between the 2 treatment groups. There was no significant difference in the risk of major bleeding with P2Y12i monotherapy as compared with aspirin (0.97, 95% CI 0.66 - 1.43, I2=0). Results were consistent irrespective of the P2Y12i. ConclusionP2Y12i monotherapy is associated with a significant reduction in atherothrombotic events as compared with aspirin alone without an increased risk of major bleeding.